1 / 17

Work Package 4

Work Package 4. Information on epidemiology of rare cancers. Riccardo Capocaccia and Sandra Mallone Cancer Epidemiology Unit Istituto Superiore di Sanità , Rome - Italy. Work Package 4: Epidemiology of rare cancers. Partners involved Associated:

orsen
Download Presentation

Work Package 4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Work Package 4 Information on epidemiology of rare cancers RiccardoCapocaccia and Sandra Mallone Cancer Epidemiology Unit IstitutoSuperiorediSanità, Rome - Italy

  2. Work Package 4:Epidemiology of rare cancers Partners involved Associated: INT, UEDIN, IKNL, ECPC, NOH, NCR, CSF, OILJ Collaborating: RCE, EPAAC, ESO, INSERM, EUROCARE, ESMO, LeukaNet, ECCO

  3. WP 4 Epidemiology of rare cancers Objectives To revise the list of rare cancers To collect and disseminate information on: - updated epidemiological indicators - the health care pathways for rare cancers Deliverable (No.7) Report on the health care pathway study and on the updated epidemiological indicators

  4. WP 4 Epidemiology of rare cancers Milestones Consensus meeting to revise list of rare cancers Partners meeting to discuss quality check and analysis necessary to update epidemiological indicators and estimate trends Meeting with CRs, together with WP5,to discuss health care pathway study

  5. WP 4 Epidemiology of rare cancers List of rare cancer The list of rare cancers which derives from the ICD-O-3 (186 identified rare cancers - around 4 million people in the European Union affected by rare cancers) will be revised and updated (refinements suggested by previous analyses, new entities) A consensus meeting is envisioned to convene the group of international experts and oncologic societies to revise the list. A contact will be established with NCI rare cancers study group: which level of coordination

  6. WP 4 Epidemiology of rare cancers List of rare cancers Work Programme • 7-8 / 2012: definition of the working group (basically the RARECARE wg) • 9 / 2012: circulating the present list and proposed amendments • 9-11 / 2012: discussion by email or forum on RARECARE website • 11 /2012: meeting for final delivery • 12/ 2012: possibility for a second meeting, if necessary • 1 /2013: new list available for endorsement from scientific associations and for analyses

  7. WP 4 Epidemiology of rare cancers Updated epidemiological indicators Cancer registries and data RARECARENet project will analyze incidence and follow-up data on cancer cases diagnosed in 1978-2007 and followed-up until 2008 from more than 100 population-based cancer registries (CR) in 30 European Countries*. This activity will be carried out in collaboration with the EUROCARE project and all contributing European CRs, after seeking permission to use the EUROCARE-5 database. *Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Slovakia (new joining countries).

  8. WP 4 Epidemiology of rare cancers Updated epidemiological indicators Analysis -1 • Incidencerateswill be provided for malignant cancers including cases diagnosed between 2000 and 2007, byscancerentity, sex, and country (and geographical area). • Othermacro-indicators: GDP level, TNEH level ? • Joint Point method will be used for incidence trend analysis in the period 1990 to 2007.

  9. WP 4 Epidemiology of rare cancers Updated epidemiological indicators Analysis -2 • Absolute and relative survival of patients diagnosed between 2000 and 2007 (i.e. patients diagnosed 5,10 or more years ago) will be provided according to the Ederer II method. • Three possible different approaches: • Cohort 2000-2004, follow-up to 2008 • Period 2005-2007 • Complete 2000-2007 • Estimateswillbegivenbycancerentity, sex, and country (and geographical area)

  10. WP 4 Epidemiology of rare cancers Updated epidemiological indicators Analysis -3 • Survival time trends for consecutive triennia (1990 – 2007) will be estimated by using multiple regression models* to assess the mutual effect of age, sex, country ( and geographic area) and possibly stage, on risk of death and to obtain relative excess risk (RER) for categories of the same variable. RER quantify the extent to which the hazard of death in a given category differs from the hazard in the reference category, after taking into account the background risk of death in the general population. *Hakulinen and Dickman et al. (Hakulinen 1982, Dickman et al., 2004).

  11. WP 4 Epidemiology of rare cancers Updated epidemiological indicators Analysis -4 • Estimates of observed prevalence, i.ethe observed number or proportion of cancer survivors per 100,000 population will be obtained form CRs incidence and follow-up data at the index date of 31 December 2008, by using the counting method. Prevalence proportions will be disaggregated by cancer entity, age, sex and time since diagnosis. • The completeness index method will be used to estimate the number of prevalent cases who were diagnosed before the start of cancer registration.

  12. WP 4 Epidemiology of rare cancers Health care pathways for rare cancers Cancer registries and data • A selection of cancer registries will send also information on the hospital of diagnosis/treatment of cancer cases. • Participant national registries: Finland, Ireland, Bulgaria, Slovenia and Netherlands. Other registries can join • Confidentiality problems regarding both patients and individual hospitals will be considered by shaping the published output according to the local legislation.

  13. WP 4 Epidemiology of rare cancers Health care pathways for rare cancers Issues • In which hospitals are rare cancers most frequently diagnosed/treated ? • Is there an association between hospital case volumes and (stage-adjusted) survival ? Is there an impact of the differing socio economical and organizational contexts on survival across countries ?

  14. WP 4 Epidemiology of rare cancers Health care pathways for rare cancers Selected CRs Definition of Centers of Expertise Hospitals data Patients data WP 5 Criteria and Info for Centers of Expertise WP 4 Info on epidemiology Volumes, Outcome WP 7 List of Centers of Expertise

  15. WP 4 Epidemiology of rare cancers High Resolution studies on rare cancers Data to be collected • Patient characteristics: age at diagnosis, sex, date of diagnosis; • Tumour characteristics: stage at diagnosis, tumour size,recurrencies, comorbidity; • Treatment (radioterapy, chemotherapy, surgery); • Date of treatment(s); • Case volume defined as the number of diagnosis/operations performed per year; • Second opinion, re-operation, free margins, multidisciplinary teams etc.

  16. WP 4 Epidemiology of rare cancers High Resolution studies on rare cancers Analysis Relative Survival will be estimated by using multiple regression models* to assess the mutual effect of the previous variables on risk of death and to obtain relative excess risk (RER) for categories of the same variable.

  17. WP 4 Epidemiology of rare cancers Timetable

More Related